Core Viewpoint - Vivos Therapeutics has announced a collaboration with SoundHealth to enhance public awareness and access to innovative airway and sleep health technologies, aiming to improve treatment for breathing-related sleep disorders [1][2][3] Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for breathing and sleep issues, particularly obstructive sleep apnea (OSA) [10][12] - The company has FDA clearance for its devices, which are designed for both adults and children suffering from various severity levels of OSA [10][11] Collaboration Details - The partnership will utilize Vivos' network of over 2,000 trained dentists and sleep healthcare providers to distribute SoundHealth's Sonu® platform, which includes the FDA-cleared Sonu® Band and the new Spatial Sleep™ band [2][3] - SoundHealth's products employ personalized vibro-acoustic neuromodulation to enhance nasal breathing and promote restful sleep [2][4] Product Innovations - The Sonu Band is recognized as the first FDA-cleared AI-enabled wearable for treating nasal congestion, comparable to intranasal steroids, and has been shown to improve CPAP user compliance [4] - The Spatial Sleep band utilizes personalized acoustic resonance therapy to facilitate quicker sleep onset and longer sleep duration through active neural entrainment [5] Technology Utilization - SoundHealth's technology includes a smartphone camera-based facial scanning and voice biomarker system, which will assist Vivos' clinical providers in screening and monitoring sleep disorders [3][6] - The Sonu smartphone app tracks airway health in real-time, allowing for active patient monitoring throughout their treatment journey [6] Market Context - The global sleep technology sector is valued at approximately $30 billion, with a significant shift from passive monitoring to active airway interventions [8] - There is a high prevalence of undiagnosed sleep-disordered breathing, with nearly 80% of cases remaining unrecognized, highlighting the need for innovative treatment solutions [8][9] Health Implications - Untreated sleep-disordered breathing is linked to a 140% increased risk of heart failure and a 30% higher risk of coronary heart disease, emphasizing the importance of airway health in overall wellness [7]

Core Viewpoint - Vivos Therapeutics has announced a collaboration with SoundHealth to enhance public awareness and access to innovative airway and sleep health technologies, aiming to improve treatment for breathing-related sleep disorders [1][2][3] Group 1: Collaboration Details - The partnership will utilize Vivos' network of over 2,000 trained dentists and sleep healthcare providers to distribute SoundHealth's Sonu platform, which includes the FDA-cleared Sonu® Band and the new Spatial Sleep™ band [2][3] - Vivos will act as a reseller for SoundHealth's products, leveraging SoundHealth's extensive craniofacial dataset and technology for educational and distribution initiatives [3] Group 2: Product Information - The Sonu Band is the first FDA-cleared AI-enabled wearable for treating nasal congestion, comparable to intranasal steroids, and has no side effects [4] - The Spatial Sleep band uses personalized acoustic resonance therapy to promote rapid sleep onset and longer sleep duration through active neural entrainment [5] - Both devices utilize smartphone cameras to create a CT-quality anatomical model for personalized therapeutic stimulation [5] Group 3: Health Impact and Market Insights - The collaboration addresses significant health risks, as untreated sleep-disordered breathing is linked to a 140% increased risk of heart failure and a 30% higher risk of coronary heart disease [7] - The global sleep technology market is valued at approximately $30 billion, with a shift from passive tracking to active airway interventions, highlighting the need for better diagnosis and treatment of sleep disorders [8][9] - Over 1 billion people are affected by obstructive sleep apnea (OSA), with 80% remaining undiagnosed, indicating a substantial market opportunity for innovative treatments [11]